ACR Applauds NRC for Adding IR to Medical Advisory Committee
ACR welcomes a new IR seat on the NRC advisory committee, strengthening expertise for radionuclide therapy, licensing and patient care.
Read moreACR® has received inquiries from radiology providers regarding the availability of iodinated contrast media in the United States following a recently resolved concern. While industry reports indicate that production is essentially normal, higher than usual ordering volumes may be contributing to variability in availability at the department or site level. As a result, distributor allocation strategies may still be in place to help ensure general availability.
During this period, ACR recommends that providers order only the volumes necessary to meet patient care needs and avoid excess ordering (e.g., buffering reserves), which may contribute to allocation constraints. If issues arise with orders, providers should contact their contrast media sales representatives to discuss immediate needs.
ACR continues to actively monitor the situation on behalf of its members and will update this notice if the available information changes.
ACR Applauds NRC for Adding IR to Medical Advisory Committee
ACR welcomes a new IR seat on the NRC advisory committee, strengthening expertise for radionuclide therapy, licensing and patient care.
Read moreAC Update Regards Lung Diseases
Stay current with ACR Appropriateness Criteria updates featuring new and revised guidance for lung disease imaging.
Read moreFY27 NIH Appropriations
ACR urges Congress to finalize FY27 NIH funding, protecting biomedical research, medical innovation and advances in patient care.
Read more